Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. - Wikidata - wikimedia - TriplyDB

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

http://www.wikidata.org/entity/Q34428346

about

Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells Recent advances in coeliac disease Inducing and Administering Tregs to Treat Human Disease Recovery of endocrine function after islet and pancreas transplantation Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience Targeting the trimolecular complex Stem cell therapy for diabetes mellitus Insulitis in human type 1 diabetes: a comparison between patients and animal models Immunotherapy in autoimmune type 1 diabetes Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case Determining disease intervention strategies using spatially resolved simulations IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes Bioluminescence imaging reveals dynamics of beta cell loss in the non-obese diabetic (NOD) mouse model Prevention of house dust mite induced allergic airways disease in mice through immune tolerance Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Toward beta cell replacement for diabetes Graves' ophthalmopathy Genetics, pathogenesis and clinical interventions in type 1 diabetes Immune therapy in type 1 diabetes mellitus Type 1 diabetes: translating mechanistic observations into effective clinical outcomes Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic β-cell injury in vitro and in vivo Agent-Based Modeling in Systems Pharmacology The role of TNF-α in mice with type 1- and 2- diabetes Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target Type 1 diabetes mellitus.Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation.Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.2011 Update: antigen-specific therapy in type 1 diabetes Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.Antibodies to watch in 2010

P2860

Q21245299-740D2A08-C075-4D64-B2D2-39835BC64A0C Q22306523-A6D45063-8633-498A-985F-D948C9F90E7F Q26772723-4F603ED1-A215-484B-BF60-453732390148 Q26822596-66C7EEEA-03DE-4B4C-B684-308AD44B7F99 Q26850621-4F50C812-184C-40C2-9D0D-11ED231E1825 Q26864985-C52BC276-B221-4E07-A057-38ED11982F6D Q27011453-E735C94D-B369-4A37-B439-6BBA9CE92752 Q27023712-4385C43E-01ED-497B-BE6D-95BE913E2A52 Q27025619-72A4E9CF-202D-43EB-8A70-9F45B12E58CA Q27028100-CA4A7C23-CA56-466D-9BEE-11713B16B763 Q27301846-516BC2F7-E7A5-4C7A-BBDB-A6E8E3A6ABE2 Q27303126-E1FFBA8F-BAF9-4596-8F7F-AAFAA73E1AD8 Q27312395-0BF7A442-BF9F-48A1-9674-04BF2B5779A9 Q27331682-42957AD4-25E4-45E1-8E54-D9ECB4F6AF02 Q27687598-74B39D29-F267-4907-B0F7-7FC47CE4B426 Q27691806-FFE11AF6-887B-4453-8679-B6D6DBECD5F9 Q28071490-E6499A5A-FA56-4538-9F5C-F06B1BB0F685 Q28081034-8716D7E8-799E-4153-80AB-0B4F70ABA18D Q28083650-5D90F0D8-7123-4E8C-87A6-0B794A81C5D7 Q28274196-AC95929F-77CC-4794-B40B-20E54124D8C1 Q28281029-E399C3B8-490D-4521-A5BA-536FEC95B226 Q28282846-CCB89AA7-7CF9-4FE9-B1DC-64A13F085404 Q28287737-40461180-3B1D-4E84-AB4A-C1EFA1C057C5 Q28554636-19896D12-E5D0-488F-8B38-9B21BF74D057 Q28575131-18022182-AEA2-4EAE-84EA-A419C7AE0344 Q28575315-40C29BD3-1234-44F6-AC21-1D3992534069 Q28602444-FAC74BE0-2276-48C1-88CF-93CBE97FC1AB Q28730016-E6224192-BB34-431D-9BC6-06179ED74953 Q28750209-AD286D23-93EC-4AA0-897E-33324D5B29E1 Q30235021-97237DE1-A9F5-40D6-976C-4046DFA3FE8F Q30430008-BE8271C6-9951-4E04-9749-D8726C8C2D04 Q30521476-2AB1FD48-A740-4D2F-8738-FD176D24CAC5 Q33506644-CDD54B9D-D186-4525-8F4C-C5BFEC4278B1 Q33559343-1B089880-B9ED-41D6-96C3-94F9E5E6995A Q33593629-45B93393-CF70-4718-B576-E8D01A9A9464 Q33636716-C6E18D8F-DFFD-4B66-BE5C-F226F4A07241 Q33637111-BD7F83DD-EDAF-4EB9-881A-B3C3BBAE59F9 Q33639743-7B1EB966-D39D-4987-96D0-9497ADBD7AA0 Q33683730-1F974D89-E29D-4B14-BC5E-12E99385C727 Q33688243-F34F3F70-34EA-4B6F-805B-4D8C2BF6288E

P2860

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

http://www.wikidata.org/entity/Q34428346

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@ast

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@en

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@nl

type

label

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@ast

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@en

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@nl

prefLabel

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@ast

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@en

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@nl

P1433

Q34428346-FDB61698-1D47-4FA5-BD00-4C9316B713A4

P1476

Q34428346-FC7487A6-948B-4872-9DE7-BD8A0A2D2DE0

P2093

Q34428346-0216C97C-8B57-43F6-A994-E6AD4131953F

Q34428346-02F10FE2-2A3C-484E-928E-8533158114A0

Q34428346-0752D2FA-4964-4C72-8EE8-E1F39002D6DA

Q34428346-1054487F-EB5A-4B0A-A36C-89BACB7C1F51

Q34428346-2D2D8111-DC5A-46E2-964D-38E6E59EECC1

Q34428346-2FBA2ED7-D8DF-4667-9309-35008ED1E0F5

Q34428346-4D223A52-9E1B-4D75-BE7D-8CDBA4A99F68

Q34428346-5024D241-CD09-46DA-B750-D50170EF2083

Q34428346-5A8B09FC-6652-487E-AE9F-0655AE2B38B4

Q34428346-60C2C0F5-6002-422D-A484-EF3432AFB42F

P304

Q34428346-BF3BAE89-8254-4708-BFF2-0C65BDE6AC76

P31

Q34428346-257DF024-E09A-4473-A743-D0DD08E21995

P356

Q34428346-58FB2DA7-0F72-49E2-B66B-99492459156A

P407

Q34428346-5E0CB56E-13DC-4B91-AA11-65E63B2D360F

P433

Q34428346-E19724A6-3DA0-4A36-B6ED-5F235FEE8663

P478

Q34428346-8997AFBC-CDB9-4CAE-AC12-6B06B50823AF

P50

Q34428346-1F3EE7DC-527C-4E04-9C6B-CA52CF571BE2

Q34428346-21AD559A-01F6-4970-82B9-CB3F3B89BE2D

Q34428346-6D02D0EB-6E51-40D8-B798-72B13D68C878

Q34428346-715EFEDB-A597-4DB7-A933-C9651D67FB1A

Q34428346-FF2A3D89-6747-4B5D-BA3E-E22F466FCDD6

P577

Q34428346-F8565A01-48EB-4FEE-8805-E210B91A96DD

P698

Q34428346-45CFB512-2AC5-463F-ADD7-FE8B679356CF

P921

Q34428346-3590C9FF-BC7E-4158-8468-5BC190408867

Q34428346-7924DE95-3820-4247-9527-E6746553A00D

Q34428346-965C1B31-99FC-42E1-BB26-4A2121A8F7F2

P356

P1433

The New England Journal of Medicine

P1476

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

@en

P2093

Anette G Ziegler

http://www.w3.org/2001/XMLSchema#string

Bart Keymeulen

http://www.w3.org/2001/XMLSchema#string

Christophe De Block

http://www.w3.org/2001/XMLSchema#string

Daniel Pipeleers

http://www.w3.org/2001/XMLSchema#string

Denis Pierard

http://www.w3.org/2001/XMLSchema#string

Eleanor Berrie

http://www.w3.org/2001/XMLSchema#string

Evy Vandemeulebroucke

http://www.w3.org/2001/XMLSchema#string

Frans Gorus

http://www.w3.org/2001/XMLSchema#string

Geoff Hale

http://www.w3.org/2001/XMLSchema#string

Ilse Weets

http://www.w3.org/2001/XMLSchema#string

P304

2598-2608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA043980

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

352

http://www.w3.org/2001/XMLSchema#string

P50

Lucienne Chatenoud

Jean-François Bach

Chantal Mathieu

Herman Waldmann

Laurent Crenier

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15972866

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes